Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Bain Capital
Deal Size : $3,300.0 million
Deal Type : Acquisition
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Details : Tanabe Pharma will continue to build on its legacy of medical innovation in internal product development including MT-210 (roluperidone), being developed for schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 07, 2025
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Bain Capital
Deal Size : $3,300.0 million
Deal Type : Acquisition
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Minerva Receives Complete Response Letter from FDA for Roluperidone NDA
Details : MIN-101 (roluperidone) blocks serotonin, sigma, and α-adrenergic receptors, involved in brain function regulation, and is being evaluated for treating negative symptoms in schizophrenia patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MIN-101 (roluperidone) is an investigational drug that has been shown to block serotonin, sigma and α-adrenergic receptors that are all involved in the regulation of important brain functions, including mood, cognition, sleep, and anxiety.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2023
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $20.0 million
Deal Type : Private Placement
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Details : Minerva intends to use the net proceeds to support potential regulatory approval in the U.S., commercialization activities and market launch of MIN-101 (roluperidone), which is being developed for the treatment of negative symptoms in schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $20.0 million
Deal Type : Private Placement
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MIN-101 (roluperidone) is a compound that has been shown to block serotonin, sigma and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. It is being developed to treat the negative symptoms of patients wit...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Roluperidone (MIN-101) has been designed to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation and thought and movement disorders.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The MIN-101 (roluperidone) clinical development program aims to provide effective treatment for negative symptoms of schizophrenia, a significant unmet medical need in a large patient population.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MIN-101 (roluperidone) is a compound that has been shown to block serotonin, sigma and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety to treat negative symptoms of patients with schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Roluperidone at both doses was safe and well tolerated, and treatment-emergent adverse events (TEAE) were generally mild to moderate in severity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable